title: Phase II Clinical Study of Radium-223 Chloride (BAY 88-8223) in Japanese Patients With Symptomatic Castration-Resistant Prostate Cancer (CRPC) With Bone Metastases.
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D015415:Biomarkers; D001859:Bone Neoplasms / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D059248:Chemoradiotherapy; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D011868:Radioisotopes / Q000008:administration & dosage / Q000009:adverse effects; D011883:Radium / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers; D011868:Radioisotopes; C581106:radium Ra 223 dichloride; D011883:Radium